스포츠베팅 | Cases and Studies in Sports Betting | 体育博彩
- date : 2015-05-20 01:10|hit : 2507
-
- Review] Biomarkers: unrealized potential in sports doping analysis
-
DocNo of ILP: 3077
Doc. Type: Review
Title: Biomarkers: unrealized potential in sports doping analysis
Authors: Teale, P; Barton, C; Driver, PM; Kay, RG
Full Name of Authors: Teale, Phil; Barton, Chris; Driver, Philip M.; Kay, Richard G.
Keywords by Author:
Keywords Plus: GROWTH-FACTOR-I; RECOMBINANT-HUMAN-ERYTHROPOIETIN; HUMAN PLASMA PROTEOME; MASS-SPECTROMETRY; IGF-I; HORMONE ABUSE; ELECTROSPRAY-IONIZATION; ANABOLIC-STEROIDS; ALTERED ERYTHROPOIESIS; CANCER DIAGNOSTICS
Abstract: The fight against doping in sport using analytical chemistry is a mature area with a history of approximately 100 years in horse racing and at least 40 years in human sport. Over that period, the techniques used and the breadth of coverage have developed significantly. These improvements in the testing methods have been matched by the increased sophistication of the methods, drugs and therapies available to the cheat and, as a result, testing has been a reactive process constantly adapting to meet new threats. Following the inception of the World Anti-Doping Agency, research into the methods and technologies available for human doping control have received coordinated funding on an international basis. The area of biomarker research has been a major beneficiary of this funding. The aim of this article is to review recent developments in the application of biomarkers to doping control and to assess the impact this could make in the future.
Cate of OECD: Biological sciences
Year of Publication: 2009
Business Area: other
Detail Business: medicine & science
Country: England
Study Area: regulation, control, globalization, globalization, review, review, beneficiary, drug, cancer
Name of Journal: BIOANALYSIS
Language: English
Country of Authors: [Teale, Phil; Barton, Chris; Driver, Philip M.; Kay, Richard G.] Quotient Biores Ltd, HFL Sport Sci, Fordham B7 5WW, Cambs, England
Press Adress: Teale, P (reprint author), Quotient Biores Ltd, HFL Sport Sci, Newmarket Rd, Fordham B7 5WW, Cambs, England.
Email Address: pteale@hfl.co.uk
Citaion:
Funding: World Anti-Doping Authority; British Horseracing Authority
Lists of Citation: Anderson L, 2006, MOL CELL PROTEOMICS, V5, P573, DOI 10.1074/mcp.M500331-MCP200; Anderson NL, 2004, MOL CELL PROTEOMICS, V3, P311, DOI 10.1074/mcp.M300127-MCP200; Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; Schenk S, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-41; Armanini D, 2002, BRIT J SPORT MED, V36, P148, DOI 10.1136/bjsm.36.2.148; Ashenden MJ, 2001, J SPORT SCI, V19, P831, DOI 10.1080/026404101753113778; Azzazy HME, 2009, CLIN BIOCHEM, V42, P435, DOI 10.1016/j.clinbiochem.2009.01.001; Bahrke MS, 2004, CURR OPIN PHARMACOL, V4, P614, DOI 10.1016/j.coph.2004.05.006; Bailly-Chouriberry L, 2008, ANALYST, V133, P270, DOI 10.1039/b713712e; Baoutina A, 2008, J GENE MED, V10, P3, DOI 10.1002/jgm.1114; Barton C, 2009, PROTEOMICS, V9, P3058, DOI 10.1002/pmic.200800737; Barton ER, 2006, APPL PHYSIOL NUTR ME, V31, P791, DOI 10.1139/H06-054; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; BAUMANN G, 1991, ENDOCR REV, V12, P424; Becker KF, 2006, CURR MED CHEM, V13, P1831, DOI 10.2174/092986706777452506; Bidlingmaier M, 2003, J ENDOCRINOL INVEST, V26, P924; *BIKERADAR, WADA SUPP UCI BIOL P; Boateng J, 2009, PROTEOM CLIN APPL, V3, P912, DOI 10.1002/prca.200800190; BOATENG J, 2007, INT J GENOM PROTEOM, V2, P912; Bobin S, 2001, ANALYST, V126, P1996, DOI 10.1039/b105022m; BREDEHOFT M, 2008, RAPID COMMUN MASS SP, V22, P447; Breidbach A, 2003, CLIN CHEM, V49, P901, DOI 10.1373/49.6.901; Brown PA, 2008, J GENE MED, V10, P564, DOI 10.1002/jgm.1170; Brown PA, 2004, MOL THER, V10, P644, DOI 10.1016/j.ymthe.2004.06.1015; Catlin DH, 2004, RAPID COMMUN MASS SP, V18, P1245, DOI 10.1002/rcm.1495; Catlin DH, 2008, J INTERN MED, V264, P99, DOI 10.1111/j.1365-2796.2008.01993.x; Chung LP, 2006, J CLIN ENDOCR METAB, V91, P671, DOI 10.1210/jc.2005-1137; Cunha SR, 2002, ENDOCRINOLOGY, V143, P4570, DOI 10.1210/en.2002-220670; Dall R, 2000, J CLIN ENDOCR METAB, V85, P4193, DOI 10.1210/jc.85.11.4193; Damsgaard R, 2006, HAEMATOL-HEMATOL J, V91, P1006; de Kock SS, 2001, RAPID COMMUN MASS SP, V15, P1191, DOI 10.1002/rcm.363; Diamanti-Kandarakis E, 2005, SPORTS MED, V35, P831, DOI 10.2165/00007256-200535100-00001; Draghia-Akli R, 2004, J Anim Sci, V82 E-Suppl, pE264; Elliott S, 2008, BRIT J PHARMACOL, V154, P529, DOI 10.1038/bjp.2008.89; Erotokritou-Mulligan I, 2008, J CLIN ENDOCR METAB, V93, P2760, DOI 10.1210/jc.2007-2801; Erotokritou-Mulligan I, 2009, CLIN ENDOCRINOL, V70, P161, DOI 10.1111/j.1365-2265.2008.03319.x; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Fisher JW, 2003, EXP BIOL MED, V228, P1; Fitch KD, 2008, ASIAN J ANDROL, V10, P384, DOI 10.1111/j.1745-7262.2008.00377.x; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/er.17.5.481; GATZIDOU E, 2009, MED SCI MONITOR, V15, P41; Georgakopoulos CG, 2007, RAPID COMMUN MASS SP, V21, P2439, DOI 10.1002/rcm.3103; Goldspink G, 2008, CURR OPIN PHARMACOL, V8, P352, DOI 10.1016/j.coph.2008.02.002; Goodsaid F, 2007, AAPS J, V9, pE105, DOI 10.1208/aapsj0901010; GORE CJ, 2004, HAEMATOLOGICA, V89, P891; Harridge SDR, 2008, ESSAYS BIOCHEM, V44, P125, DOI 10.1042/BSE0440125; Healy ML, 2005, J CLIN ENDOCR METAB, V90, P641, DOI 10.1210/jc.2004-0386; HILLENKAMP F, 1990, METHOD ENZYMOL, V193, P280, DOI 10.1016/0076-6879(90)93420-P; HOLT RI, 2008, BRIT J PHARMACOL, V54, P542; Holt RIG, 2009, GROWTH HORM IGF RES, V19, P43, DOI 10.1016/j.ghir.2008.06.001; Ilyin SE, 2004, TRENDS BIOTECHNOL, V22, P411, DOI 10.1016/j.tibtech.2004.06.005; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Kay RG, 2007, RAPID COMMUN MASS SP, V21, P2585, DOI 10.1002/rcm.3130; Keshamouni VG, 2006, J PROTEOME RES, V5, P1143, DOI 10.1021/pr050455t; Kicman AT, 2008, BRIT J PHARMACOL, V154, P502, DOI 10.1038/bjp.2008.165; Kicman AT, 1997, CLIN ENDOCRINOL, V47, P43, DOI 10.1046/j.1365-2265.1997.2111036.x; Kirsch S, 2007, J CHROMATOGR A, V1153, P300, DOI 10.1016/j.chroma.2007.03.058; Lasne F, 2002, ANAL BIOCHEM, V311, P119, DOI 10.1016/S0003-2697(02)00407-4; Lee JW, 2006, PHARM RES, V23, P312, DOI 10.1007/s11095-005-9045-3; Liu W, 2003, J CLIN ENDOCR METAB, V88, P5490, DOI 10.1210/jc.2003-030497; Ludwig JA, 2005, NAT REV CANCER, V5, P845, DOI 10.1038/nrc1739; Mardis ER, 2008, TRENDS GENET, V24, P133, DOI 10.1016/j.tig.2007.12.007; Mareck U, 2008, J MASS SPECTROM, V43, P877, DOI 10.1002/jms.1457; McHugh CM, 2005, CLIN CHEM, V51, P1587, DOI 10.1373/clinchem.2005.047845; Minunni M, 2008, TRENDS BIOTECHNOL, V26, P236, DOI 10.1016/j.tibtech.2008.02.005; MISCHAK A, 2007, PROTEOM CLIN APPL, V1, P148; Nelson AE, 2006, J CLIN ENDOCR METAB, V91, P4424, DOI 10.1210/jc.2006-0612; Nelson AE, 2008, J CLIN ENDOCR METAB, V93, P2213, DOI 10.1210/jc.2008-0402; Nelson AE, 2008, ASIAN J ANDROL, V10, P416, DOI 10.1111/j.1745-7262.2008.00395.x; Nelson M, 2003, HAEMATOLOGICA, V88, P1284; NGUYEN TV, 2008, CLIN CHEM, V54, P1265; Nicholson JK, 2008, NATURE, V455, P1054, DOI 10.1038/4551054a; Noble GK, 2007, J ANIM SCI, V85, P163, DOI 10.2527/jas.2006-210; O'Farrell PH., 1975, J BIOL CHEM, V250, P400; Paparini A, 2007, Ann Ig, V19, P303; Parisotto R, 2001, HAEMATOLOGICA, V86, P128; Parisotto R, 2000, INT J SPORTS MED, V21, P471, DOI 10.1055/s-2000-7421; Pieper R, 2003, PROTEOMICS, V3, P1345, DOI 10.1002/pmic.200300449; Popot MA, 2008, ANAL BIOANAL CHEM, V390, P1843, DOI 10.1007/s00216-008-1889-z; Popot MA, 2001, RES VET SCI, V71, P167, DOI 10.1053/rvsc.2001.0505; Powrie JK, 2007, GROWTH HORM IGF RES, V17, P220, DOI 10.1016/j.ghir.2007.01.011; Riedmaier I, 2009, J CHROMATOGR A, V1216, P8192, DOI 10.1016/j.chroma.2009.01.094; Sallet P, 2008, INT J HEMATOL, V88, P362, DOI 10.1007/s12185-008-0182-4; Sartorio A, 2004, J ENDOCRINOL INVEST, V27, P410; Saugy M, 2006, BRIT J SPORT MED, V40, P35, DOI 10.1136/bjsm.2006.027573; Schwenk JM, 2008, J PROTEOME RES, V7, P3168, DOI 10.1021/pr700890b; Segura J, 2007, ANAL BIOANAL CHEM, V388, P1521, DOI 10.1007/s00216-007-1316-x; Sharpe K, 2002, HAEMATOLOGICA, V87, P1248; Sharpe K, 2006, HAEMATOL-HEMATOL J, V91, P356; Sjoqvist F, 2008, LANCET, V371, P1872, DOI 10.1016/S0140-6736(08)60801-6; Thakkar H, 2008, ANN NY ACAD SCI, V1137, P58, DOI 10.1196/annals.1448.003; Thevis M, 2007, MASS SPECTROM REV, V26, P79, DOI 10.1002/mas.20107; Thevis M, 2009, J MASS SPECTROM, V44, P442, DOI 10.1002/jms.1584; THEVIS M, 2008, DRUG TEST ANAL, V1, P4; THEVIS M, 2008, DRUG DISCOV TODAY, V33, P59; Thevis M., 2007, MINI-REV MED CHEM, V7, P533, DOI DOI 10.2174/138955707780619590; Thevis M, 2008, MASS SPECTROM REV, V27, P35, DOI 10.1002/mas.20154; Thevis M, 2009, DEUT Z SPORTMED, V60, P66; Tonge R, 2001, PROTEOMICS, V1, P377; VanGuilder HD, 2008, BIOTECHNIQUES, V44, P619, DOI 10.2144/000112776; Velloso CP, 2008, BRIT J PHARMACOL, V154, P557, DOI 10.1038/bjp.2008.153; Vestergaard ET, 2007, J CLIN ENDOCR METAB, V92, P297, DOI 10.1210/jc.2006-1435; *WADA, WADA SCI MED PROGR; *WADA, WADA ATHL PASSP; Walker MS, 2008, INT J MOL MED, V21, P13; Wells DJ, 2008, BRIT J PHARMACOL, V154, P623, DOI 10.1038/bjp.2008.144; Zhang XW, 2007, TRENDS BIOTECHNOL, V25, P166, DOI 10.1016/j.tibtech.2007.02.006; Zhang XW, 2007, MASS SPECTROM REV, V26, P403, DOI 10.1002/mas.20132; Zolg JW, 2004, MOL CELL PROTEOMICS, V3, P345, DOI 10.1074/mcp.M400007-MCP200; GUIDELINES BLOOD SAM
Number of Citaion: 110
Publication: FUTURE SCI LTD
City of Publication: LONDON
Address of Publication: UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
ISSN: 1757-6180
29-Character Source Abbreviation: BIOANALYSIS
ISO Source Abbreviation: Bioanalysis
Volume: 1
Version: 6
Start of File: 1103
End of File: 1118
DOI: 10.4155/BIO.09.87
Number of Pages: 16
Web of Science Category: Biochemical Research Methods; Chemistry, Analytical
Subject Category: Biochemistry & Molecular Biology; Chemistry
Document Delivery Number: 644VL
Unique Article Identifier: WOS:000281409700014
[이 게시물은 HyeJung Mo…님에 의해 2015-05-20 14:29:43 GAMBLING에서 이동 됨]
- reply : 0
-
- list
-
- prev
- next